Behind myeloMATCH: A Precision Medicine Trial in AML and MDS

Harry Erba, MD, PhD, professor of medicine at Duke Cancer Institute, chair of the SWOG Leukemia Committee and co-chair of the myeloMATCH Senior Science Council, discusses myeloMATCH, a precision medicine umbrella trial for patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).

myeloMATCH includes over 2,200 sites of the National Cancer Institute (NCI), located in both the US and Canada. The NCI’s Division of Cancer Treatment and Diagnosis has worked to create cooperative research and development agreements with a number of pharmaceutical companies. This will provide different drugs to support myeloMATCH.

myeloMATCH intends to develop a portfolio of substudies to treat patients through all stages of their AML or MDS. The study will screen patients at diagnosis using genomic testing including Thermo Fisher's Ion Torrent Genexus System and assign them to a substudy based on clinical, cytogenetic, and molecular features. Once patients finish their induction treatment, they will be rescreened and may possibly be assigned to another substudy designed for a later treatment stage. This process may continue to be repeated.

The screening protocol for myeloMATCH opened in May 2024. Notably, MM1YA-CTG01 (NCT05554393), which is led by the Canadian Cancer Trials Group, MM1YA-S01 (NCT05554406), led by SWOG, and MM1OA-EA02 (NCT05564390), led by the ECOG-ACRIN Cancer Research Group are some of the myeloMATCH treatment trials that have already opened, or will be opening shortly.

Transcription:

0:09 | myeloMATCH is 1 of the 3 NCI funded adult MATCH trials. The concept of myeloMATCH is to deconstruct all of the elements of a patients’ therapeutic journey after an initial diagnosis of acute myeloid leukemia, and try to optimize our interventions for initial therapy, typically called induction chemotherapy, follow-up treatment called consolidation, the possibility to transplant, and maintenance.

0:54 | So, myeloMATCH attempts to develop clinical trials in each of these therapeutic steps to optimize outcomes for patients with acute myeloid leukemia.